Fresenius Kabi Investing $250M in Illinois Pharma Plant

German pharmaceutical company Fresenius Kabi is investing $250 million over the next decade in its Melrose Park, IL manufacturing facility.

The expansion of the site, which produces generic, sterile injectable pharmaceuticals for use in US hospitals and clinics, includes the construction of at four or more buildings that will add about 130,000 sq ft to the existing 123,267 sq ft plant, the Chicago Tribune reported. Completion is expected in 2026.

“We are creating a state-of-the-art pharmaceutical manufacturing campus that will be a showcase for our company and the production of injectable generic medicines,” Steven R. Nowicki, senior vice president of global operations for North America of Fresenius Kabi’s pharmaceuticals division said in a statement.

The company said the expansion will include the addition of fully automated aseptic filling lines that employ isolator technology, increased freeze drying capabilities, an administration building, areas for formulations and a new warehouse specifically dedicated to housing raw materials and components.

“Our goal is to expand our US manufacturing capabilities while ensuring continued compliance with increasing regulatory and quality requirements and improve production capacity and efficiency,” said Nowicki.

For related articles, news, and equipment reviews, visit our Equipment Zones